Literature DB >> 20187732

Development of pulmonary arterial hypertension in women: interplay of sex hormones and pulmonary vascular disease.

Meredith E Pugh1, Anna R Hemnes.   

Abstract

Pulmonary arterial hypertension (PAH) is a progressive disease of the pulmonary vasculature, ultimately resulting in right heart failure and death. This disease is strongly predominant in females, although little is known regarding how sex influences disease development. Recent developments highlighting the importance of estrogen metabolites in both animal models and human disease have substantially increased our understanding of PAH in women. This review will focus on general knowledge of PAH, translational and basic science data regarding sex hormones in the pulmonary vasculature and on clinical issues that are particular to women with PAH. Future directions for study include the influence of sex hormones on right ventricular responses, improving the understanding of the influence of estrogen exposure in human disease and the study of dehydroepiandrosterone in basic science and human disease.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20187732      PMCID: PMC2853883          DOI: 10.2217/whe.09.88

Source DB:  PubMed          Journal:  Womens Health (Lond)        ISSN: 1745-5057


  88 in total

1.  Genetic polymorphisms in CYP1B1, GSTA1, NQO1 and NAT2 and the risk of lung cancer.

Authors:  Mette Sørensen; Herman Autrup; Anne Tjønneland; Kim Overvad; Ole Raaschou-Nielsen
Journal:  Cancer Lett       Date:  2005-04-28       Impact factor: 8.679

Review 2.  Functional role of estrogen metabolism in target cells: review and perspectives.

Authors:  B T Zhu; A H Conney
Journal:  Carcinogenesis       Date:  1998-01       Impact factor: 4.944

3.  Mutation in the gene for bone morphogenetic protein receptor II as a cause of primary pulmonary hypertension in a large kindred.

Authors:  J H Newman; L Wheeler; K B Lane; E Loyd; R Gaddipati; J A Phillips; J E Loyd
Journal:  N Engl J Med       Date:  2001-08-02       Impact factor: 91.245

4.  Secondary pulmonary hypertension in chronic heart failure: the role of the endothelium in pathophysiology and management.

Authors:  D L Moraes; W S Colucci; M M Givertz
Journal:  Circulation       Date:  2000-10-03       Impact factor: 29.690

5.  Clinical effects of endothelin receptor antagonism with bosentan in patients with severe chronic heart failure: results of a pilot study.

Authors:  Milton Packer; John McMurray; Barry M Massie; Abraham Caspi; Vincent Charlon; Alain Cohen-Solal; Wolfgang Kiowski; William Kostuk; Henry Krum; Barry Levine; Paolo Rizzon; Jordi Soler; Karl Swedberg; Susan Anderson; David L Demets
Journal:  J Card Fail       Date:  2005-02       Impact factor: 5.712

6.  Clinical outcomes of pulmonary arterial hypertension in carriers of BMPR2 mutation.

Authors:  Benjamin Sztrymf; Florence Coulet; Barbara Girerd; Azzedine Yaici; Xavier Jais; Olivier Sitbon; David Montani; Rogério Souza; Gerald Simonneau; Florent Soubrier; Marc Humbert
Journal:  Am J Respir Crit Care Med       Date:  2008-03-20       Impact factor: 21.405

7.  Endogenous estrogen attenuates pulmonary artery vasoreactivity and acute hypoxic pulmonary vasoconstriction: the effects of sex and menstrual cycle.

Authors:  Tim Lahm; Ketan M Patel; Paul R Crisostomo; Troy A Markel; Meijing Wang; Christine Herring; Daniel R Meldrum
Journal:  Am J Physiol Endocrinol Metab       Date:  2007-06-26       Impact factor: 4.310

8.  PDE5A inhibitor treatment of persistent pulmonary hypertension after mechanical circulatory support.

Authors:  Ryan J Tedford; Anna R Hemnes; Stuart D Russell; Ilan S Wittstein; Mobusher Mahmud; Ari L Zaiman; Stephen C Mathai; David R Thiemann; Paul M Hassoun; Reda E Girgis; Jonathan B Orens; Ashish S Shah; David Yuh; John V Conte; Hunter C Champion
Journal:  Circ Heart Fail       Date:  2008-11       Impact factor: 8.790

9.  Selective estrogen receptor-alpha and estrogen receptor-beta agonists rapidly decrease pulmonary artery vasoconstriction by a nitric oxide-dependent mechanism.

Authors:  Tim Lahm; Paul R Crisostomo; Troy A Markel; Meijing Wang; Yue Wang; Jiangning Tan; Daniel R Meldrum
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2008-10-01       Impact factor: 3.619

10.  Characterization of the vasodilatory action of testosterone in the human pulmonary circulation.

Authors:  Alyson M Smith; Robert T Bennett; T Hugh Jones; Mike E Cowen; Kevin S Channer; Richard D Jones
Journal:  Vasc Health Risk Manag       Date:  2008
View more
  17 in total

1.  Kinetics of skeletal muscle O2 delivery and utilization at the onset of heavy-intensity exercise in pulmonary arterial hypertension.

Authors:  Priscila B Barbosa; Eloara M V Ferreira; Jaquelina S O Arakaki; Luciana S Takara; Juliana Moura; Rúbia B Nascimento; Luiz E Nery; J Alberto Neder
Journal:  Eur J Appl Physiol       Date:  2011-01-12       Impact factor: 3.078

2.  The sexual dimorphism associated with pulmonary hypertension corresponds to a fibrotic phenotype.

Authors:  Olga Rafikova; Ruslan Rafikov; Mary Louise Meadows; Archana Kangath; Danny Jonigk; Stephen M Black
Journal:  Pulm Circ       Date:  2015-03       Impact factor: 3.017

3.  Estrogen rescues preexisting severe pulmonary hypertension in rats.

Authors:  Soban Umar; Andrea Iorga; Humann Matori; Rangarajan D Nadadur; Jingyuan Li; Federica Maltese; Arnoud van der Laarse; Mansoureh Eghbali
Journal:  Am J Respir Crit Care Med       Date:  2011-06-23       Impact factor: 21.405

Review 4.  Sex differences and sex steroids in lung health and disease.

Authors:  Elizabeth A Townsend; Virginia M Miller; Y S Prakash
Journal:  Endocr Rev       Date:  2012-01-12       Impact factor: 19.871

Review 5.  Ovarian stimulation and embryo banking for fertility preservation in a woman with severe mixed connective tissue disease: Is it safe?

Authors:  Vasileios D Sioulas; Clarisa R Gracia
Journal:  J Assist Reprod Genet       Date:  2011-12-29       Impact factor: 3.412

6.  Gender Difference in Damage-Mediated Signaling Contributes to Pulmonary Arterial Hypertension.

Authors:  Ruslan Rafikov; Vineet Nair; Shripad Sinari; Harini Babu; Jennifer C Sullivan; Jason X-J Yuan; Ankit A Desai; Olga Rafikova
Journal:  Antioxid Redox Signal       Date:  2019-03-20       Impact factor: 8.401

Review 7.  Metabolic and hormonal derangements in pulmonary hypertension: from mouse to man.

Authors:  M E Pugh; A R Hemnes
Journal:  Int J Clin Pract Suppl       Date:  2010-11

8.  Sex-specific cardiopulmonary exercise testing parameters as predictors in patients with idiopathic pulmonary arterial hypertension.

Authors:  Ping Yuan; Hui-Juan Ni; Tian-Xiang Chen; Bigyan Pudasaini; Rong Jiang; Hui Liu; Qin-Hua Zhao; Lan Wang; Su-Gang Gong; Jin-Ming Liu
Journal:  Hypertens Res       Date:  2017-06-01       Impact factor: 3.872

9.  Cyp2c44 gene disruption exacerbated pulmonary hypertension and heart failure in female but not male mice.

Authors:  Sachindra Raj Joshi; Anand Lakhkar; Vidhi Dhagia; Ariadne L Zias; Vasiliki Soldatos; Kaori Oshima; Houli Jiang; Katherine Gotlinger; Jorge H Capdevila; Michal L Schwartzman; Ivan F McMurtry; Sachin A Gupte
Journal:  Pulm Circ       Date:  2016-09       Impact factor: 3.017

Review 10.  Estrogen paradox in pulmonary hypertension: current controversies and future perspectives.

Authors:  Soban Umar; Marlene Rabinovitch; Mansoureh Eghbali
Journal:  Am J Respir Crit Care Med       Date:  2012-05-03       Impact factor: 21.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.